{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:00:24Z","timestamp":1793041224706,"version":"4.5.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,6,4]],"date-time":"2019-06-04T00:00:00Z","timestamp":1559606400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Diabetes Association of the Republic of China"},{"name":"Taiwanese Association of Diabetes Educators"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.jfma.2019.06.001","type":"journal-article","created":{"date-parts":[[2019,6,25]],"date-time":"2019-06-25T09:40:52Z","timestamp":1561455652000},"page":"S74-S82","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"S2","title":["Trends in antidiabetic medical treatment from 2005 to 2014 in Taiwan"],"prefix":"10.1016","volume":"118","author":[{"given":"Chih-Hsun","family":"Chu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Cheng","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Yi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee-Ming","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Sin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Te","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfma.2019.06.001_bib1","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1001\/archinte.164.10.1134","article-title":"Trends in the complexity of diabetes care in the United States from 1991\u20132000","volume":"164","author":"Grant","year":"2004","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jfma.2019.06.001_bib2","doi-asserted-by":"crossref","first-page":"602","DOI":"10.7326\/0003-4819-154-9-201105030-00336","article-title":"Comparative effectiveness and safety of medication for type 2 diabetes: an update including new drugs and 2-drug combinations","volume":"154","author":"Bennett","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jfma.2019.06.001_bib3","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1185\/030079906X112598","article-title":"Glycemic control and treatment failure with pioglitazone versus glibenclamide in type 2 diabetes mellitus: a 42-month, open-label, observational, primary care study","volume":"22","author":"Hanefeld","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jfma.2019.06.001_bib4","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1001\/jama.298.10.1180","article-title":"Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials","volume":"298","author":"Lincoff","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.jfma.2019.06.001_bib5","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1177\/1479164112441524","article-title":"Alpha-glucosidase inhibitors 2012 - cardiovascular considerations and trial evaluation","volume":"9","author":"Standl","year":"2012","journal-title":"Diabetes Vasc Dis Res"},{"key":"10.1016\/j.jfma.2019.06.001_bib6","first-page":"23","article-title":"Saxagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus","volume":"5","author":"Kulasa","year":"2010","journal-title":"Core Evid"},{"key":"10.1016\/j.jfma.2019.06.001_bib7","first-page":"665","article-title":"Optimizing combination treatment in the management of type 2 diabetes","volume":"3","author":"Derosa","year":"2007","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.jfma.2019.06.001_bib8","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.jfma.2012.09.009","article-title":"National trends in anti-diabetic treatment in Taiwan, 2000\u20132009","volume":"111","author":"Chang","year":"2012","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.jfma.2019.06.001_bib9","series-title":"Diabetes fact sheet in Korea","year":"2018"},{"key":"10.1016\/j.jfma.2019.06.001_bib10","doi-asserted-by":"crossref","first-page":"e012463","DOI":"10.1136\/bmjopen-2016-012463","article-title":"Glycaemic control and antidiabetic treatment trends in primary care centres in patients with type 2 diabetes mellitus during 2007\u20132013 in Catalonia: a population-based study","volume":"6","author":"Mata-Cases","year":"2016","journal-title":"BMJ Open"},{"issue":"Suppl 2","key":"10.1016\/j.jfma.2019.06.001_bib11","doi-asserted-by":"crossref","first-page":"S305","DOI":"10.1016\/S0168-8227(14)70734-X","article-title":"A decade of diabetes care in Taiwan","volume":"106","author":"Yu","year":"2014","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.jfma.2019.06.001_bib12","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.2337\/dc13-2289","article-title":"Use of antidiabetic drugs in the U.S., 2003\u20132012","volume":"37","author":"Hampp","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jfma.2019.06.001_bib13","doi-asserted-by":"crossref","first-page":"468","DOI":"10.2337\/dc16-0985","article-title":"Trends in drug utilization, glycemic control, and rates of severe hypoglycemia, 2006\u20132013","volume":"40","author":"Lipska","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jfma.2019.06.001_bib14","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1536\/ihj.54.93","article-title":"Trends in antidiabetic prescription patterns in Japan from 2005 to 2011","volume":"54","author":"Kohro","year":"2013","journal-title":"Int Heart J"},{"key":"10.1016\/j.jfma.2019.06.001_bib15","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.2337\/dc06-9912","article-title":"Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American diabetes association and the European association for the study of diabetes","volume":"29","author":"Nathan","year":"2006","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jfma.2019.06.001_bib16","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.2337\/dc12-1235","article-title":"Ethnic differences in the relationship between insulin sensitivity and insulin response: a systematic review and meta-analysis","volume":"36","author":"Kodama","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jfma.2019.06.001_bib17","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa072761","article-title":"Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes","volume":"356","author":"Nissen","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2019.06.001_bib18","series-title":"Actos (Pioglitazone): Ongoing safety review-potential increased risk of bladder cancer","year":"2011"},{"key":"10.1016\/j.jfma.2019.06.001_bib19","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2019.06.001_bib20","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","article-title":"Alogliptin after acute coronary syndrome in patients with type 2 diabetes","volume":"369","author":"White","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2019.06.001_bib21","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1501352","article-title":"Effect of sitagliptin on cardiovascular outcomes in Type 2 diabetes","volume":"373","author":"Green","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2019.06.001_bib22","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1001\/jama.2018.18269","article-title":"Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial","volume":"321","author":"Rosenstock","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.jfma.2019.06.001_bib23","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in Type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2019.06.001_bib24","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in Type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2019.06.001_bib25","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2019.06.001_bib26","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2337\/dc08-9025","volume":"32","author":"Nathan","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jfma.2019.06.001_bib27","unstructured":"Rajasri Chandra. The role of pharmacogenomics in precision medicine. Available from: https:\/\/www.mlo-online.com\/role-pharmacogenomics-precision-medicine. [Accessed 22 August 2017]."},{"key":"10.1016\/j.jfma.2019.06.001_bib28","doi-asserted-by":"crossref","first-page":"8","DOI":"10.7603\/s40681-014-0008-z","article-title":"Personalized medicine in type 2 diabetes","volume":"4","author":"Liao","year":"2014","journal-title":"Biomedicine (Taipei)"},{"key":"10.1016\/j.jfma.2019.06.001_bib29","doi-asserted-by":"crossref","first-page":"18050","DOI":"10.18632\/oncotarget.14951","article-title":"Pharmacogenetics of dipeptidyl peptidase 4 inhibitors in a Taiwanese population with type 2 diabetes","volume":"8","author":"Liao","year":"2017","journal-title":"Oncotarget"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664619303560?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664619303560?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T14:40:08Z","timestamp":1760539208000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929664619303560"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":29,"alternative-id":["S0929664619303560"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2019.06.001","relation":{},"ISSN":["0929-6646"],"issn-type":[{"value":"0929-6646","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Trends in antidiabetic medical treatment from 2005 to 2014 in Taiwan","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2019.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Formosan Medical Association. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}